The post RUNE Technical Analysis Feb 15 appeared on BitcoinEthereumNews.com. RUNE’s 24-hour trading volume remains low at the 6.63 million dollar level, while overallThe post RUNE Technical Analysis Feb 15 appeared on BitcoinEthereumNews.com. RUNE’s 24-hour trading volume remains low at the 6.63 million dollar level, while overall

RUNE Technical Analysis Feb 15

For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

RUNE’s 24-hour trading volume remains low at the 6.63 million dollar level, while overall market participation appears weak; this indicates that selling pressure is decreasing within the downtrend and giving possible accumulation signals. Despite the slight price rise, the lack of volume confirmation questions the sustainability of the move.

Volume Profile and Market Participation

RUNE’s current volume profile stands out with a 24-hour trading volume of 6.63 million dollars. This level is noticeably low compared to recent weekly averages; for example, there is a decline of around 30-40% compared to previous days. Low volume indicates limited market participation and, despite the dominance of the downtrend, emphasizes that sellers are not aggressive. In the volume profile, the Value Area (VA) region around $0.42 is narrowed; this reflects that buyers have not yet established full dominance, but sellers are also showing signs of exhaustion. Retail investors seem to dominate among market participants, while institutional flows are quiet. Combined with Supertrend’s bearish signal ($0.51 resistance), this calm in volume could be a preparatory phase for a trend reversal. For a healthy volume profile, at least a 50% increase is expected in upward breakouts; the current low level limits volatility and strengthens the consolidation tendency.

Accumulation or Distribution?

Accumulation Signals

Despite the price remaining below EMA20 ($0.45) within the downtrend, the decrease in volume evokes classic accumulation patterns. Especially at the $0.4161 support level (70/100 score), holding without volume spikes suggests that big players might be accumulating at the bottom. With RSI at 36.93 approaching the oversold region, the volume decline confirms weakening selling momentum. In MTF analysis, the 4 support levels on 1D and 1W timeframes (2S 1D, 2S 1W) provide strong ground for accumulation. If volume increases while price tests the $0.4225 resistance, it would confirm accumulation; the current low participation may be concealing hidden buys.

Distribution Risks

From a distribution perspective, the low volume despite a +1.20% daily change is warning. Even if price jumps upward without volume confirmation, this could be a weak rally and potential trap. Resistance weight on the 3D timeframe (0R/1S) and BTC’s bearish supertrend increase distribution risk in altcoins. Without breaking the $0.5712 resistance (60/100), if volume does not increase, distribution could accelerate toward the $0.3500 support. To watch: A sudden price drop with volume spikes would be a clear distribution signal.

Price-Volume Alignment

There is a clear divergence between price action and volume: The daily +1.20% rise is not supported by low volume; this shows it is not a healthy bullish move. There is a positive divergence between MACD’s positive histogram (bullish) and RSI’s low level, but the lack of volume does not confirm it. Volume is low in down moves and similar in up moves – this indicates the trend is tiring and we are waiting for volume confirmation. For a healthy uptrend, volume must be 1.5 times the average during resistance tests; the current situation increases fakeout risk. If the $0.4161 support holds without volume, it is bullish; if broken, a bearish volume increase is expected.

Big Player Activity

Institutional-level activity is limited by low volume; according to on-chain data, whale flows are calm, but the 8 strong levels in MTF (total 5S/5R balance) show that big players are watching these levels. The 3 resistances on 1W may indicate institutional selling reserves, but equal distribution on 1D maintains accumulation balance. As the POC (Point of Control) in the volume profile approaches $0.42, whales can be considered accumulating positions in this range. Silence without sudden spikes reflects strategic waiting; if BTC dominance rises, institutional outflow risk in RUNE increases. Although exact positions cannot be known, low volume implies big buyers are hiding. Check detailed data for RUNE Spot Analysis and RUNE Futures Analysis.

Bitcoin Correlation

While BTC at $69,798 with +1.34% is slightly recovering, the downtrend continues; supertrend is bearish and main supports are $68,848-$65,415. Altcoins like RUNE are highly correlated with BTC (%0.85+), so if BTC cannot break $71,248 resistance, volume decline in RUNE will deepen. If BTC slips to $60,000, RUNE’s bearish target $0.1922 (22 score) activates. Conversely, if BTC reaches $75,165, RUNE becomes bullish at $0.5900 (13 score). Rising BTC dominance crushes alt volumes; for RUNE, BTC’s $68,848 support is critical – expect an altcoin selling wave on breakout.

Volume-Based Outlook

Volume-focused outlook is cautiously optimistic: Low participation weakens the downtrend, preparing ground for accumulation. In the short term, if $0.4225 resistance breaks with volume, it opens the way to $0.51; otherwise, test of $0.3500. In the long term, if volume exceeds average combined with MTF supports, bullish reversal. Risk: Downward move without volume due to BTC bearishness. Strategy: Wait for volume increase, follow spot and futures analyses for spot/futures positions. Overall, remain cautious until volume confirms price – a 50%+ volume surge is essential for a healthy trend.

This analysis uses Chief Analyst Devrim Cacal’s market views and methodology.

Strategy Analyst: David Kim

Macro market analysis and portfolio management

This analysis is not investment advice. Do your own research.

Source: https://en.coinotag.com/analysis/rune-technical-analysis-february-15-2026-volume-and-accumulation

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09